Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry
The COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensiv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1791736 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849731603408879616 |
|---|---|
| author | Peng Xu Xiangyu Xing Keying Yu Zhiguo Lv Huijing Cui Yuhang Shi Tianying Chang Dongmei Zhang Yibin Zhang Kai Wang Jing Lu Qingxia Huang Xiangyan Li Yingzi Cui Li Shi Tan Wang Junqi Niu Jian Wang |
| author_facet | Peng Xu Xiangyu Xing Keying Yu Zhiguo Lv Huijing Cui Yuhang Shi Tianying Chang Dongmei Zhang Yibin Zhang Kai Wang Jing Lu Qingxia Huang Xiangyan Li Yingzi Cui Li Shi Tan Wang Junqi Niu Jian Wang |
| author_sort | Peng Xu |
| collection | DOAJ |
| description | The COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensive efforts to identify effective drugs against the virus. To date, a large number of clinical trials addressing various aspects of COVID19 have been registered in the Chinese Clinical Trial Registry (ChiCTR), including more than 200 interventional studies. Under such an urgent circumstance, the scope and quality of these clinical studies vary significantly. Hence, this review aims to make a comprehensive analysis on the profiles of COVID-19 clinical trials registered in the ChiCTR, including a wide range of characteristics. Our findings will provide a useful summary on these clinical studies since most of these studies will encounter major challenges from the design to completion. It will be a long road for the outcomes of these studies to be published and international collaboration will help the ultimate goals of developing new vaccines and anti-viral drugs. |
| format | Article |
| id | doaj-art-99438c8ccf2d417ea5c14dca705a16a0 |
| institution | DOAJ |
| issn | 2222-1751 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-99438c8ccf2d417ea5c14dca705a16a02025-08-20T03:08:29ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-01911695170110.1080/22221751.2020.1791736Profiles of COVID-19 clinical trials in the Chinese Clinical Trial RegistryPeng Xu0Xiangyu Xing1Keying Yu2Zhiguo Lv3Huijing Cui4Yuhang Shi5Tianying Chang6Dongmei Zhang7Yibin Zhang8Kai Wang9Jing Lu10Qingxia Huang11Xiangyan Li12Yingzi Cui13Li Shi14Tan Wang15Junqi Niu16Jian Wang17Neurology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaDepartment of Hepatology, The First Hospital of Jilin University, Changchun, People’s Republic of ChinaCardiovascular Medicine Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaNeurology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaTraditional Chinese Medicine Department, Nanguan District Traditional Chinese Medicine Hospital, Changchun, People’s Republic of ChinaDepartment of Gerontology, The Changchun Hospital of TCM, Changchun, People’s Republic of ChinaGCP Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaScientific Research Office, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaJilin Ginseng Academy, Jilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaGCP Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaRespiratory Medicine Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaRespiratory Medicine Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaDepartment of Hepatology, The First Hospital of Jilin University, Changchun, People’s Republic of ChinaNeurology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People’s Republic of ChinaThe COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensive efforts to identify effective drugs against the virus. To date, a large number of clinical trials addressing various aspects of COVID19 have been registered in the Chinese Clinical Trial Registry (ChiCTR), including more than 200 interventional studies. Under such an urgent circumstance, the scope and quality of these clinical studies vary significantly. Hence, this review aims to make a comprehensive analysis on the profiles of COVID-19 clinical trials registered in the ChiCTR, including a wide range of characteristics. Our findings will provide a useful summary on these clinical studies since most of these studies will encounter major challenges from the design to completion. It will be a long road for the outcomes of these studies to be published and international collaboration will help the ultimate goals of developing new vaccines and anti-viral drugs.https://www.tandfonline.com/doi/10.1080/22221751.2020.1791736COVID-19anti-viral drugTraditional Chinese Medicineclinical trialsvaccine |
| spellingShingle | Peng Xu Xiangyu Xing Keying Yu Zhiguo Lv Huijing Cui Yuhang Shi Tianying Chang Dongmei Zhang Yibin Zhang Kai Wang Jing Lu Qingxia Huang Xiangyan Li Yingzi Cui Li Shi Tan Wang Junqi Niu Jian Wang Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry Emerging Microbes and Infections COVID-19 anti-viral drug Traditional Chinese Medicine clinical trials vaccine |
| title | Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry |
| title_full | Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry |
| title_fullStr | Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry |
| title_full_unstemmed | Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry |
| title_short | Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry |
| title_sort | profiles of covid 19 clinical trials in the chinese clinical trial registry |
| topic | COVID-19 anti-viral drug Traditional Chinese Medicine clinical trials vaccine |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1791736 |
| work_keys_str_mv | AT pengxu profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT xiangyuxing profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT keyingyu profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT zhiguolv profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT huijingcui profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT yuhangshi profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT tianyingchang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT dongmeizhang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT yibinzhang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT kaiwang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT jinglu profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT qingxiahuang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT xiangyanli profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT yingzicui profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT lishi profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT tanwang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT junqiniu profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry AT jianwang profilesofcovid19clinicaltrialsinthechineseclinicaltrialregistry |